▮ DFV TERMINAL
--:--:-- UTC SIGN IN
F1 Terminal / AIM

AIM — AIM ImmunoTech Inc.

—
NYSE · Health Care · Biotechnology · CIK 946644 ·
Last close
$0.40
Market Cap
$10.78M
52W High
$1.62
52W Low
$0.21
ADV30
56,672,047
Next earnings
—
AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. It is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 22,000 18,000 -2,226,000 -3,023,000 8,585,000 5,816,000 6,460,000
Dec 2025 21,000 -19,000 -2,952,000 -4,175,000 5,782,000 2,985,000 15,565,000
Sep 2025 26,000 -42,000 -2,447,000 -3,284,000 5,494,000 2,347,000 11,571,000
Jun 2025 25,000 15,000 -2,646,000 -2,794,000 4,129,000 476,000 10,675,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-11,315,000
Investing CF
$918,000
Financing CF
$15,315,000
CapEx
$-413,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-10.93
As of
2026-06-07

Balance + Analyst (yfinance extras)

Retained Earnings
$-443,809,000
Inventory
—
Receivables
$0
ST Investments
$63,000
EBIT TTM
$-12,284,000
Pretax Income TTM
$-13,276,000
Interest Exp TTM
$992,000
Analysts
2

Yahoo Snapshot (yfinance, live)

Total Revenue
$94,000
EBITDA
$-10,076,000
Free Cash Flow
$-12,052,875
Enterprise Value
$4,607,787
Total Cash
$5,879,000
Total Debt
$4,574,000
Shares Out
26,952,742
Trailing EPS
$-4.31
Book Value
$-3.19
ROE
—
ROA
-86.6%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 88,000 -11,664,000 -13,958,000 5,782,000 15,565,000 — -10,957,000
Dec 2024 170,000 -19,772,000 -17,320,000 8,608,000 9,930,000 — -14,888,000
Dec 2023 202,000 -31,916,000 -28,962,000 19,381,000 9,147,000 — -21,267,000
Dec 2022 141,000 -19,923,000 -19,445,000 40,488,000 2,020,000 — -16,108,000

TTM Snapshot

Revenues TTM
$120,000
NetIncome TTM
$-15,925,000
OpCashFlow TTM
$0
Assets (Latest)
$29,440,000
Forward EPS
$-0.52

Peers — same industry

TickerNameMarket CapLastDaily %
CUBT Curative Biotechnology Inc $9.96M $1.30 —
INTS INTENSITY THERAPEUTICS, INC. $9.93M $3.67 —
JSPR Jasper Therapeutics, Inc. $13.20M $0.47 —
BCLI BRAINSTORM CELL THERAPEUTICS INC. $8.77M $0.80 —
ZEOX Zeo ScientifiX, Inc. $13.32M $1.70 —

News headlines (Yahoo Finance, 1h cache)

AIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity Deficiency
2026-06-15 12:01 · Yahoo
AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rules
2026-06-09 13:29 · Yahoo
AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of P
2026-06-08 12:33 · Yahoo
AIM ImmunoTech Releases Virtual Investor ‘What This Means’ Video Segment Discussing Ampligen’s Potential in Ebola Virus Disease Preparedness
2026-06-04 12:55 · Yahoo
AIM Stock Soars Over 200% As Pancreatic Cancer Trial Hits Enrollment Milestone Early — CEO Sees 'Value-Inflection Period' Ahead
2026-06-01 14:19 · Yahoo
AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones
2026-06-01 12:58 · Yahoo
AIM ImmunoTech Announces Emerging Ebola Opportunity for Ampligen Amid Escalating Global Health Concerns and WHO Emergency Declaration
2026-05-27 12:47 · Yahoo
AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement
2026-05-20 19:02 · Yahoo
AIM ImmunoTech Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to June 2027, Enhancing Financial Flexibility and Supporting Strategic Clinical Prior
2026-05-19 12:02 · Yahoo
AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer
2026-05-14 12:41 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.
SEC EDGAR filings → · StockAnalysis.com → · OpenInsider →